Literature DB >> 24649282

Prognostic significance of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in biliary tract cancer patients receiving adjuvant 5-fluorouracil-based chemotherapy.

Kwan Woo Kim1, Hyuk-Chan Kwon2, Sung-Hyun Kim2, Sung Yong Oh2, Suee Lee2, Ji Hyun Lee2, Myung Hwan Roh2, Min Chan Kim3, Ki Han Kim3, Young Hoon Kim3, Young Hoon Roh3, Jin Sook Jeong4, Hyo-Jin Kim1.   

Abstract

Biliary tract cancer (BTC) is a relatively uncommon type of cancer, accounting for ∼4% of the malignant neoplasms of the gastrointestinal tract. The aim of this study was to determine whether the expression of thymidylate synthase (TS), thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) predict clinical outcome in BTC patients treated with adjuvant 5-fluorouracil (5-FU)-based chemotherapy. TS and TP expression were found to be significantly correlated with cancer location (P=0.044 and 0.031, respectively). The multivariate analysis revealed that age [hazard ratio (HR)=2.157, P=0.008], stage (HR=2.234, P<0.001), resection margin status (HR=2.748, P=0.004) and TP expression (HR=2.014, P=0.039) were independently associated with overall survival (OS).

Entities:  

Keywords:  5-fluorouracil; biliary tract cancer; thymidine phosphorylase

Year:  2013        PMID: 24649282      PMCID: PMC3915652          DOI: 10.3892/mco.2013.166

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  27 in total

1.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.

Authors:  D Salonga; K D Danenberg; M Johnson; R Metzger; S Groshen; D D Tsao-Wei; H J Lenz; C G Leichman; L Leichman; R B Diasio; P V Danenberg
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

2.  Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.

Authors:  H-C Kwon; M S Roh; S Y Oh; S-H Kim; M C Kim; J-S Kim; H-J Kim
Journal:  Ann Oncol       Date:  2007-03       Impact factor: 32.976

3.  Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival.

Authors:  D Edler; U Kressner; P Ragnhammar; P G Johnston; I Magnusson; B Glimelius; L Påhlman; G Lindmark; H Blomgren
Journal:  Clin Cancer Res       Date:  2000-02       Impact factor: 12.531

4.  Methotrexate selection of long-term culture initiating cells following transduction of CD34(+) cells with a retrovirus containing a mutated human dihydrofolate reductase gene.

Authors:  Naoko Takebe; Li-Cheng Xu; Karen L MacKenzie; Joseph R Bertino; Malcolm A S Moore
Journal:  Cancer Gene Ther       Date:  2002-03       Impact factor: 5.987

5.  Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.

Authors:  Hideki Yamada; Hisae Iinuma; Toshiaki Watanabe
Journal:  Oncol Rep       Date:  2008-03       Impact factor: 3.906

6.  Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma.

Authors:  Tadahiro Takada; Hodaka Amano; Hideki Yasuda; Yuji Nimura; Takashi Matsushiro; Hiroyuki Kato; Takukazu Nagakawa; Toshimichi Nakayama
Journal:  Cancer       Date:  2002-10-15       Impact factor: 6.860

Review 7.  Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis.

Authors:  N S Brown; R Bicknell
Journal:  Biochem J       Date:  1998-08-15       Impact factor: 3.857

8.  Thymidine phosphorylase is angiogenic and promotes tumor growth.

Authors:  A Moghaddam; H T Zhang; T P Fan; D E Hu; V C Lees; H Turley; S B Fox; K C Gatter; A L Harris; R Bicknell
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

Review 9.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

10.  Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival.

Authors:  J-S Kim; M-A Kim; T M Kim; S-H Lee; D-W Kim; S-A Im; T-Y Kim; W H Kim; H-K Yang; D S Heo; Y-J Bang; K-U Lee; K-J Choe; N K Kim
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

View more
  1 in total

1.  Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer.

Authors:  Masafumi Ikeda; Izumi Ohno; Hideki Ueno; Shuichi Mitsunaga; Yusuke Hashimoto; Takuji Okusaka; Shunsuke Kondo; Mitsuhito Sasaki; Yasunari Sakamoto; Hideaki Takahashi; Rina Hara; Shingo Kobayashi; Osamu Nakamura; Chigusa Morizane
Journal:  Invest New Drugs       Date:  2018-07-11       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.